Recent Share Performance Snapshot

Vertex Pharmaceuticals (VRTX) has attracted attention after a mixed stretch for the stock, with a small 1 day gain, pressure over the past week and month, and a positive past 3 months and 1 year track record.

Against that backdrop, investors are weighing how the company’s US$12,001.3m in revenue, US$3,953.2m in net income and current share price of US$460.87 fit with its longer term total returns and perceived valuation.

Recent trading has been choppy, with a 1 day share price return of 0.92% and softer 7 and 30 day share price returns, while longer term total shareholder returns over 3 and 5 years remain strongly positive.

If Vertex’s mix of volatility and long run compounding has your attention, it could be a good moment to scan the broader market using our screener of 32 healthcare AI stocks as another area of potential opportunity.

So with Vertex trading at US$460.87, reporting US$12,001.3m in revenue and US$3,953.2m in net income, is the current price still leaving a margin of value on the table, or is the market already pricing in future growth?

Most Popular Narrative: 8.6% Undervalued

According to the narrative by Vestra, a fair value of $504.04 sits above Vertex’s last close at $460.87, framing the stock as modestly undervalued on that view.

Vertex Pharmaceuticals (VRTX) has entered a transformative era where its identity is shifting from a "Cystic Fibrosis (CF) company" to a multi-disease powerhouse. Following its Q4 fiscal 2025 earnings report on February 12, 2026, the stock demonstrated resilience, trading at $495.43 as of February 27. The company delivered a nuanced "beat-and-miss" performance: while non-GAAP EPS of $5.03 narrowly missed the consensus of $5.05, total revenue climbed 10% year-over-year to $3.19 billion, surpassing Wall Street estimates. This growth was anchored by the launch of Alyftrek (the next-gen triple combo for CF) and the initial commercial ramp of Casgevy, their CRISPR-based gene therapy.

Curious how a CF heavyweight gets to that $504.04 fair value? The narrative leans on earnings growth, expanding revenue lines, and margin assumptions that quietly do the heavy lifting.

Vestra’s fair value uses a discounted cash flow framework, applying a specific discount rate to future estimates rather than today’s earnings multiples. The narrative anchors on projected growth in non CF treatments, the evolving CF franchise and cash generation, which together are used to justify the small gap between the calculated value and the current share price.

Result: Fair Value of $504.04 (UNDERVALUED)

However, this hinges on CF cash flows holding up and new therapies like Casgevy and non CF programs scaling as expected; any stumble could quickly challenge that 8.6% undervalued case.

Another Angle On Valuation

Vestra’s narrative leans on a discounted cash flow view, but our check using the P/E ratio paints a tighter picture. Vertex trades on 29.6x earnings, slightly above its own fair ratio of 29.1x and higher than the US biotech industry at 21.4x, while sitting below the peer average of 40.4x.

That mix of a near-fair ratio, an industry premium and a peer discount suggests the market is already pricing in a lot of quality, with only a thin margin for error. How comfortable are you with paying up for this earnings profile?

Next Steps

If this mix of optimism and caution around Vertex has you thinking, act while the details are fresh and weigh the upside for yourself with 3 key rewards.

Looking for more investment ideas?

If this Vertex deep dive sparked ideas, do not stop here. Use the Simply Wall St Screener now so you do not overlook other compelling setups.

• Spot potential mispricings early by scanning our hand picked list of 46 high quality undervalued stocks that pair quality fundamentals with appealing valuations.
• Strengthen your income core by reviewing 14 dividend fortresses that focus on higher yielding companies with supporting fundamentals.
• Sleep easier by checking 63 resilient stocks with low risk scores that prioritize resilient balance sheets and lower overall risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.